 This study is phase II of the ICH-ADAPT study. The investigators hypothesize that aggressive antihypertensive therapy will alter the natural history of heamatoma growth, improving outcomes after Intracranial Hemorrhage ICH. The previous phase I ICH-ADAPT study has established the safety of early BP treatment. 